Purpose: Paroxysmal kinesigenic dyskinesia (PKD) and epilepsy are thought to have a shared genetic etiology. PRRT2 has been identified as a causative gene of both disorders. In this study, we aim to explore the potential novel causative gene in a PRRT2-negative family with three individuals diagnosed with PKD or genetic epilepsy with febrile seizures plus (GEFS+). Methods: Clinical data were collected from all the affected and unaffected members of a PKD/GEFS+ family. The Brain magnetic resonance imaging and 24 h video-EEG of all three affected members were analyzed. Targeted gene-panel sequencing was used to detect the genetic defect in genomic DNAs of three affected and five normal individuals. Co-segregation analysis of putatively pathogenic mutations with the phenotype was carried out in all the family members alive to examine the inheritance status.
Introduction
Paroxysmal kinesigenic dyskinesia (PKD) is a rare neurological disorder characterized by recurrent attacks of dystonia or chorea triggered by sudden movements [1] . Genetic epilepsy with febrile seizures plus (GEFS + ) is an epilepsy syndrome characterized by heterogeneous phenotypes ranging from mild disorders to epileptic encephalopathies [2] . A recent study indicated that GEFS+ can either be sporadic or familial [3] . It has been suggested that there is a shared genetic background underlies the concurrence of GEFS+ and PKD in the same family [4] .
Mutations in PRRT2 have been identified as a cause of PKD and GEFS+, however, more than 50% of primary PKD and most of GEFS+ cases remain genetically unexplained [5, 6] . Here we identified a novel gene for PKD and GFES+, CHRNA4, by using a gene-panel approach in a PRRT2-negative family with different individuals exhibiting PKD and GFES+.
Materials and methods

Patients
The proband (III-1) was referred to the neurology clinic in Xijing Hospital for clinical consultation and genetic diagnosis. The index case and his relatives underwent clinical evaluation, based on personal interviews, patients' charts, and brain magnetic resonance imaging (MRI) and a continuous video electroencephalograms (video-EEG, 24 h) monitoring. The diagnosis of PKD and GEFS+ adhered to the recommendation proposed by Bhatia KP [1] and recognized criteria (GEFS+ is a complex epilepsy syndrome characterized by heterogeneous phenotypes, including febrile seizures (FS), febrile seizures plus (FS+) in which attacks with fever continued beyond 6 years, or/and afebrile seizures occurred. FS or FS+ may also be accompanied by generalized or focal seizures) [2] , respectively. The study was approved by the ethics committee of Xijing Hospital, and written informed consents were obtained from all the participants and their parents/legal guardians.
Molecular and bioinformatics analysis
Genomic DNAs were extracted from all the alive family members (three affected and five unaffected individuals) using standard protocols. Mutations in PRRT2 were excluded by Sanger sequencing in the proband. The amplified DNAs of proband and his sister were captured with a PKD and epilepsy related Gene-Panel, containing 163 genes (Supplementary Table 1 ), using biotinylated oligo-probes. Paired-end sequencing was performed on a nextgeneration HiSeq2000 sequencer (Illumina, San Diego, California). The SNPs/indels were filtered if they showed up with a frequency >5% in several databases, such as dbSNP138, 1000 Genomes, and 1000 MyGenostics inhouse Asia database. The probably pathogenic mutations were then predicted according to the SIFT, PolyPhen and Mutation Taster. All putatively causative mutations identified by gene panel were confirmed and tested for co-segregation with the phenotypes using Sanger sequencing.
Results
Clinical features of affected individuals
The Table 1 showed the clinical characteristics of the three affected individuals in the kindred. The family pedigree is presented in Fig. 1A . The 12-year-old proband (III-1) started to present episodic dyskinesia three or four times per day since 11 years old. He has exhibited symptoms of choreoathetosis and dsytonia which were mostly triggered by sudden movements and only occurred during daytime. Those attacks usually lasted for less than 30 s, and did not cause any loss of consciousness. He was given oxcarbazepine monotherapy, which markedly controlled the attacks. The patient III-2 was born full term with normal delivery, but suffered from more than a dozen febrile seizures between the ages of three and seven. She also had myoclonic seizures without fever every week between the ages of six and eleven. Besides, she experienced three times of GTCS during wakefulness without any trigger or aura since 14 years old. Her seizures were significantly controlled under the treatment of levetiracetam, and she is the only person who had febrile seizures in the family. Their father (II-1) started to suffer from dsytonia (usually lasted for less than 10 s) triggered by sudden movements without loss of consciousness at the age of ten. His symptoms of dystonia spontaneously disappeared by the age of 30 without any treatment. Except for II-1, III-1, III-2, other five family members are normal and never had febrile seizures. Interictal 24 h video-EEG and brain MRI of all the affected members are normal.
Genetic findings
Through gene-panel sequencing of individuals III-1and III-2, three variants were found in CTNNA3, ELP4, CHRNA4 respectively in the III-1, and a novel variant was identified in CHRNB2 in the individual III-2 who also carries abovementioned missense mutations in CTNNA3 and CHRNA4. Those aberrations were validated and confirmed with conventional Sanger sequencing in all eight alive family members (Supplemental Table 3 ). Segregation analysis of these mutations was carried out in the kindred, and demonstrated that only the mutation in CHRNA4 was fully co-segregated with the phenotypes in the family (Fig. 1A, B) . Thus, mutations in CTNNA3, ELP4, and CHRNB2 were excluded from the consideration of major genes that caused PKD or GEFS+ in this family. The p.Val327Met mutation in CHRNA4 affects the amino acid of the third transmembrane domain (M3) of the protein (Fig. 1C) . Bioinformatic analysis predicted that the Val327Met substitution was "probably damaging" by PolyPhen (score = 1), "deleterious" by SIFT (score = 0) and "Disease-causing" by MutationTaster (score = 1), respectively. This mutation was absent in the Exome Variant Server and the Exome Aggregation Consortium set containing approximately 61,000 exomes, supporting its pathogenic role. Silico analysis the UGENE software suggested that the valine at codon 327 was highly conserved from various species (Fig. 1D ).
Discussion
Our study revealed that CHRNA4 may be a novel gene for PKD and GEFS+, with the same mutation fully co-segregated in a threegeneration family. CHRNA4 encodes a4 subunit of the neuronal nicotinic acetylcholine receptor (nAChR), frequently assembled with the b2 subunit (encoded by CHRNB2) into a heteropentamer a4b2-nAChR. The tertiary structure of each subunit is similar, comprising four transmembrance domains (M1-M4) with N and C ternmini on the extracellular side [7] . The a4b2-nAChR mutations were previously reported to be mainly located in the M2 and M3 regions [8] . Experiments on the Xenopus oocyte expression system have demonstrated that all the mutations display an increased sensitivity to acetylcholine (ACh) [9] . Moreover, a mouse model carrying CHRNA4 variants showed that an increased response to ACh significantly enhances cortical GABAergic transmission and further contributes to epileptogenesis through inhibitory resetting of synchronization [10] . It's hypothesized that increased a4b2-mediated transmitter releasing causes an abnormal synchronization of neuronal networks, and the following hyper-synchronization produces epileptic seizures. In our patients, the demonstrated mutation (p.Val327Met) is located in the M3 region of a4 subunit, and it may alter the physiological properties of the receptor by increasing its sensitivity to ACh. CHRNA4 has been originally reported as an important molecular cause of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), a rare motor seizures arising during non-rapid eye movement sleep frequently with normal intellect [11] . In our study, three individuals in a PRRT2-negative family were found to have CHRNA4 variants (III-1 and II-1 presented with PKD, and III-2 had GEFS+). Thus, our study broadened the phenotypic spectrum of CHRNA4.
The underlying mechanisms of phenotypic heterogeneity within the family may involve variable expressivity of a single causative gene, or modifying genes, or epigenetic factors. In our study, the mutation in CHRNB2 ((NM_000748 c.1381C > T) was also found in II-1 (diagnosed with PKD) and III-2 (diagnosed with GEFS +), but not in III-1 and other relatives. Previous studies reported that CHRNB2 is traditionally involved in ADNFLE with an incomplete penetrance (approximately 75%) and mutations in CHRNB2 also increased the sensitivity to ACh [12] . Consistently, we argue that CHRNB2 had an incomplete penetrance in the family (the CHRNB2 mutation was not expressed in patient II-1 diagnosed with PKD, while it exerted a functional effect on patient III-2 diagnosed with GEFS+). Therefore, we suspect that CHRNB2 may play a modifier role in the phenotype of III-2 and probably account for the different clinical phenotypes in the family.
There is a long-known relationship between PKD and epilepsy, given the paroxysmal character, involuntary movements, short duration of attacks, and coexistence in the same family [4] . Recently, SCN8A, a major epilepsy gene encoding a voltage-gated sodium channel, has also been demonstrated to cause PKD [13] . And the findings of CHRNA4 in this study further provided a pathophysiological link for the co-occurrence of PKD and epilepsy.
Conclusion
We reported a novel fully co-segregating CHRNA4 mutation in three individuals with PKD/GEFS+ of a PRRT2-negative family. This finding extends the genotypic-phenotypic spectrum of combined epileptic and dyskinetic syndromes. 
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